Brief: Mendus Says Alison Trial Reaches Primary Objective

Mendus AB (publ)

20/06/2024 11:42

June 20 (Reuters) - Mendus AB (publ)  IMMUN.ST :
    * ALISON TRIAL DATA PRESENTED AT ESMO GYNAECOLOGICAL CANCERS
DEMONSTRATE TUMOR-DIRECTED IMMUNE RESPONSES IN THE MAJORITY OF
PATIENTS TREATED WITH VIDIDENCEL
    * MENDUS AB (PUBL) - TRIAL REACHED ITS PRIMARY OBJECTIVE OF
INDUCING TUMOR-DIRECTED IMMUNE RESPONSES IN AT LEAST 10 PATIENTS
TREATED WITH VIDIDENCEL
    * MENDUS AB (PUBL) - VIDIDENCEL-INDUCED IMMUNE RESPONSES
AGAINST
TUMOR ANTIGENS THAT ARE REGULARLY UPREGULATED IN HGSC WERE
OBSERVED IN 10 OUT OF 15 PATIENTS EVALUATED SO FAR
    * MENDUS AB (PUBL) - VIDIDENCEL TREATMENT ONLY GAVE MILD
ADVERSE
REACTIONS, PREDOMINANTLY AT SITE OF INJECTION

Source text for Eikon:  ID:nMFN67qWXz 
Further company coverage:  IMMUN.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))